Amgen, newer rivals could threaten Novo Nordisk and Eli Lilly's weight loss drug dominance
Related Articles
-
Healthy Returns: Eli Lilly, Novo Nordisk make progress toward boosting weight loss drug supply
Eli Lilly and Novo Nordisk are boosting supply of their weight loss drugs, while Apple Watch's heart-monitoring tech was approved for use in clinical studies.
-
How weight loss drugs like Wegovy are transforming the weight loss industry
Since weight loss drugs have come online, the weight loss industry has ballooned from about $76 billion a year to almost $90 billion in 2023.
-
Franklin Resources Inc. Lowers Stock Holdings in Eli Lilly and Company (NYSE:LLY)
Franklin Resources Inc. trimmed its stake in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 3.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,322,197 shares of the company’s stock after selling 84,980 shares during the quarter. Franklin Resources Inc. […]